A Semmelweis Szimpózium hivatalos nyelve az angol.

17th November

Pathogenesis and molecular genetics of hematological malignancies
13:45-
14:00

Opening ceremony

14:00-
14:20

Jude Fitzgibbon (London, UK):
Genetic and epigenetic alterations of small B-cell lymphomas 

14:25-
14:45

Csaba Bödör (Budapest, Hungary):
The genomic landscape of chronic lymphocytic leukemia

14:50-
15:10

András Matolcsy (Budapest, Hungary):
Richter transformation of chronic lymphocytic leukaemia

15:15-
15:35

Roland Jager (Vienna, Austria):
Pathogenesis of myeloproliferative neoplasms

 

15:35-16:00

 

Coffee break

16:00-
16:20

Leonie Saft (Stockholm, Sweden):
Novel aspects of myelodysplastic syndromes

16:25-
16:45

Péter Király (Budapest, Hungary):
Genetic predisposition to myeloid malignancies

16:45-
17:00

Daniel Veres (Budapest, Hungary):
Artificial intelligence guided therapy design in oncohematology

17:00-
19:00

Poster session
2nd floor of the Department of Pathology and Experimental Cancer Research

 

18th November

Morning session: 
New trends in haematopoietic stem cell transplantation

09:00-
09:10

Tamás Masszi (Budapest, Hungary):
Introduction: Activity and history of Hungarian  haemopoietic stem cell transplantation

09:15-
09:35

Robert Gale (USA):
Lessons on haemopoietic stem cell transplantation

09:40-
10:00

Francesco Dazzi (London, UK):
Mesenchymal stromal cells, biology, production and clinical use in haematology

10:05-
10:25

Krisztián Németh  (Wisconsin, USA):
Mesenchymal stem cells and macrophages: old friends with new perspectives

10:30-
10:50

Eliane Gluckman (Paris, France):
Cord blood transplantation 

10:50-11:10

Coffee break

11:10-
11:20

Zoltán Pós (Budapest, Hungary):
Lymphocyte homing in graft versus host disease

11:25-
11:35

János Sinkó (Budapest, Hungary):
Viral infections following stem cell transplantation

11:40-
11:50

Gergely Kriván (Budapest, Hungary):
Virus specific T-cell treatment following stem cell transplantation

11:55-
12:05

Tamás Masszi (Budapest, Hungary):
T-cell replete graft with post-transplant cyclophosphamide in haploidentical and mismatched VUD SCT

12:10-
12:30

Jane Apperley (London, UK):
Cellular therapy –  What is the future?

   

Afternoon session: Multidisciplinarity in onco-hematology

14:00-
14:20

Richard Clark (Liverpool, UK):
Optimal management and avoidance of adverse events of treatment in chronic myeloid leukemia

14:25-
14:35

Péter Holló (Budapest, Hungary):
Cutaneous side effects of molecularly targeted treatments in oncohematology

14:40-
15:00

Judit Demeter (Budapest, Hungary):
Experience with low dose vemurafenib treatment in hairy cell leukemia

15:05-
15:25:

Roch Houot (Rennes, France):
Why immunooncology in hematology?

15:30-
15:50

Zsolt Nagy (Budapest, Hungary):
Myeloma bone disease: from bisphosphonates to inhibitors of RANK ligand and beyond